Sai Parenteral’s IPO

Listed Mainboard
Min Investment
₹14,896
38 Shares
Min Investment
₹14,896 · 38 Shares
Price Band ₹372–392
Lot Size 38 shares
Issue Size ₹409 Cr
Listed At ₹405.00 +3.3%
Subscribed 1.08×
Listed On BSE & NSE

Sai Parenteral’s IPO Listing Day Performance

Sai Parenteral’s listed on BSE & NSE on 02 April 2026 at ₹405.00, a 3.32% premium over the issue price of ₹392. A retail investor allotted one lot of 38 shares gained ₹494 at the listing price.

Issue price
₹392
upper band
Listing price
₹405.00
pre-open auction
Listing gain
+3.32%
+₹13 per share
Profit per application
+₹494
38 shares

Demand going into listing

Subscribed overall1.08×
QIB1.73×
NII2.45×
Retail0.12×
Listing price = opening price from the exchange's pre-open call auction on listing day. Watch live price

Market Sentiment

Grey Market Premium What is GMP?
GMP not available yet
This section updates automatically once data is available.
Subscription Status
QIB
1.73x
NII
2.45x
bNII (>10L)
3.56x
sNII (2-10L)
0.24x
Retail
0.12x
Total
1.08x
Updated: Mar 30, 2026 5:51 pm IST
Analysis Score 39 / 100
Weak Signals
Data: 45%
Subscription Score · 67% weight 30
Financial Health · 33% weight 57
Weighted average of the parts above; updates as GMP and subscription change. not investment advice.

IPO Details

Price Band₹372–392 per equity share
Face Value₹5 Per Equity Share
Lot Size 38 shares (Min ₹14,896)
Total Issue Size ₹409.00 crore
Fresh Issue₹285.00 crore
Offer For Sale₹124.00 crore
Fresh vs OFS
Fresh 70% · to the company OFS 30% · to selling shareholders
Issue TypeBook build Issue
Lead Manager Arihant Capital Markets Ltd.
Registrar Bigshare Services Pvt. Ltd.
Listing atBSE & NSE
BSE Code544742
NSE SymbolSAIPARENT
ISININE0H9F01037
Listing Price₹405.00
Listing Gain+3.32%

Day-wise Subscription (times subscribed)

QIB
NII
Retail
Total
Each panel has its own scale.
Category Day 1 Day 2 Final Final Final Final
QIB 0.00x 0.60x 1.71x 1.71x 1.71x 1.73x
NII 0.15x 1.01x 2.36x 2.36x 2.36x 2.45x
bNII > ₹10L 0.21x 1.49x 3.43x 3.43x 3.43x 3.56x
sNII 2-10L 0.03x 0.04x 0.23x 0.23x 0.23x 0.24x
Retail 0.03x 0.05x 0.12x 0.12x 0.12x 0.12x
Total 0.04x 0.41x 1.05x 1.05x 1.05x 1.08x

Market Lot Size

Category Lots Shares Amount (₹)
Retail Minimum 1 38 ₹14,896
Retail Maximum 13 494 ₹1,93,648
S-HNI Minimum 14 532 ₹2,08,544
S-HNI Maximum 67 2,546 ₹9,98,032
B-HNI Minimum 68 2,584 ₹10,12,928

IPO Reservation

QIB 20% NII 15% Retail 35% Anchor 30%
Category Shares Offered Shares %
QIB20,85,65920.00%
NII (HNI)15,64,24315.00%
bNII > ₹10L10,42,82910.00%
sNII < ₹10L5,21,4145.00%
Retail36,49,90135.00%
Anchor31,28,48530.00%
Total1,04,28,288

Financial Analysis

Financial Data

ROE
15.09%
ROCE
28.92%
NAV/Share
₹35.98
Revenue Growth
5.52%
Profit Margin
8.81%

Financial Performance

2025 vs 2024 Revenue +5.5% Profit (PAT) +71.4% Total Assets +1.6%
Metric 2023 2024 2025 Sep 2025
Revenue 97.03 155.18 163.74 89.43
Expense 89.78 142.63 143.84 78.27
Profit (PAT) 4.38 8.42 14.43 7.76
Total Assets 133.96 268.10 272.39 376.24
Values in Crores (₹)

Peer Comparison

Company EPS P/E Market Cap (Cr)
Sai Life Sciences Limited 8.83 107.70 8
InnovaCaptab Limited 22.41 32.45 13
Senores Pharmaceuticals Limited 16.12 64.30 7
Gland Pharma Limited 42.40 44.71 8
Industry Average - 62.29 -
Peer median P/E 62.3x across 5 listed peers

Promoters & Holding Pattern

Promoters: Anil Kumar Karusala, Vijitha Gorrepati and Karusala Aruna

Shareholding No. of Shares Holding %
Promoter Holding Pre Issue 3,69,08,823 61.23%

Strengths & Risks

Strengths
  • Solid profit margin — 8.8%.
  • Strong return on equity — 15%.
  • Mostly fresh capital — proceeds fund the company's growth, not an exit.
Risks & Concerns

Our data checks haven't flagged a specific concern for Sai Parenteral’s — but that isn't a clean bill of health. Read the risk-factors section of the RHP, which lists company-specific risks our data can't capture.

From this issue's live data. Not investment advice — read the RHP.

Company Information

Sai Parenteral’s at a glance

From the company's description: “Sai Parenteral’s Ltd., founded in 2001, is one of the leading pharmaceutical companies focused on R&D and manufacturing of pharmaceutical products.”

Sai Parenteral’s is raising ₹409 crore through an IPO on the BSE and NSE mainboard. Of that, ₹285 crore is a fresh issue — new shares, with the money going to the company — and ₹124 crore is an offer for sale by existing shareholders, who keep those proceeds; 70% of the issue therefore reaches the business. Main stated uses of the fresh money: Capacity expansion and upgradation of manufacturing facilities (₹111 crore), Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed… (₹36 crore) and Working capital requirements (₹33 crore).

Revenue went from ₹97.03 crore in 2023 to ₹164 crore in 2025, up 69% over 2 years. Profit after tax went from ₹4.38 crore to ₹14.43 crore, a net margin of 8.8% in the latest year.

Written from the issue's offer-document figures shown on this page. Not investment advice.

Company Contact Information

Sai Parenteral’s Ltd., Plot No 39, 5th floor, Lavanya Arcade, Jayabheri Enclave, Gachibowli, K.V.Rangareddy, Seri Lingampally, Hyderabad, Telangana, 500032

Objects of the Issue

Purpose Amount (Cr)
Capacity expansion and upgradation of manufacturing facilities 110.80
Establishment of a new R&D Centre; 18.02
Repayment / prepayment of certain outstanding borrowings 20.00
Working capital requirements 33.00
Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and 36.00
General corporate purposes -

Resources & Documents

Anchor Investors

Anchor Bidding Date
March 23, 2026
Shares Offered to Anchors
31,28,485
Lock-in End (30 Days, 50%)
April 29, 2026
Lock-in End (90 Days, 50%)
June 28, 2026

Sai Parenteral’s IPO - Quick Take

Sai Parenteral’s has set a price band of Rs 372–Rs 392 per share for an issue size of Rs 409 crore. The stock listed with a 3.32% gain versus its issue price on April 02, 2026.

The issue is promoted by Anil Kumar Karusala, Vijitha Gorrepati and Karusala Aruna with Arihant Capital Markets Ltd. acting as lead manager. Net proceeds will primarily be used towards capacity expansion and upgradation of manufacturing facilities (Rs 111 crore) and establishment of a new R&D Centre; (Rs 18 crore).

On fundamentals, the company is posting revenue growth of 5.5%, a profit margin of 8.8%, return on equity of 15.1% in its most recent reported period. Listed peers in this segment include InnovaCaptab Limited (P/E 32.45x, market cap Rs 13 crore) and Sai Life Sciences Limited (P/E 107.70x, market cap Rs 8 crore) — useful reference points when evaluating the issue's pricing relative to where the broader sector is trading.

On our data-signal score, the combined signals for this issue currently read weak — several key indicators are reading below average. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.

Sai Parenteral’s IPO: Lead Manager & Registrar Track Record

How the firm running this issue and its registrar have fared on the other IPOs we track. Each firm's figures leave out Sai Parenteral’s itself, so they describe what came before it.

Mainboard IPOs, last 12 months
  • Sai Parenteral’s listed at +3.3% on day one; the median of 113 listings was +7% (better than 37% of them).
  • Subscribed 1.08x against a median of 20.56x across 111 issues (higher than 3%).
  • Average listing-day move across all 114 Mainboard listings we track: +13.6%.
Lead manager and registrar record on other IPOs we track
Firm Other IPOs Listed at / above issue Avg move Median
Arihant Capital Markets Ltd. Lead manager First we track — — —
Bigshare Services Pvt. Ltd. Registrar 61 18 MB · 43 SME 67% 41 of 61 Check allotment →
What a lead manager does

A SEBI-registered merchant banker that runs the issue: due diligence, drafting the offer document, setting the price band with the company, and marketing the IPO to investors.

What a registrar does

Finalises the basis of allotment, credits shares to demat accounts, releases blocked funds for unsuccessful bids and handles investor queries about the issue.

Listing-day move = exchange opening price vs issue price (band ceiling where the final price isn't recorded). Counts cover IPOs we track only. Past listings don't predict this one; this is not investment advice.

Frequently Asked Questions

Sai Parenteral’s listed at Rs 405.00 on 02 April 2026, against an issue price of Rs 392 — a 3.32% premium.

+3.32% at the listing price — Rs 13 per share, or Rs 494 on the minimum retail application of 38 shares.

The price band of Sai Parenteral’s IPO is Rs 372 to Rs 392 per share. Face value is Rs 5 per share.

The total issue size of Sai Parenteral’s IPO is Rs 409 crore, comprising fresh issue of Rs 285 crore and offer for sale (OFS) of Rs 124 crore.

The lot size of Sai Parenteral’s IPO is 38 shares. The minimum application is 1 lot (38 shares), requiring an investment of Rs 14,896. Maximum retail application is 13 lots (494 shares, approx Rs 1,93,648).

Sai Parenteral’s IPO opens for subscription on March 24, 2026 and closes on March 27, 2026. Anchor investor bidding is scheduled for March 23, 2026.

The expected allotment date for Sai Parenteral’s IPO is March 30, 2026. Refunds for unsuccessful applicants are expected on April 01, 2026.

Sai Parenteral’s IPO is scheduled to list on April 02, 2026 on both BSE and NSE. BSE script code: 544742, NSE symbol: SAIPARENT, ISIN: INE0H9F01037.

Sai Parenteral’s IPO was subscribed 1.08 times overall by the close of bidding — retail at 0.12x, QIB at 1.73x, NII at 2.45x.

Based on the final retail subscription of 0.12x for Sai Parenteral’s IPO, the estimated retail allotment probability is approximately 100.0%. This is a high probability of allotment.

The registrar for Sai Parenteral’s IPO is Bigshare Services Pvt. Ltd. After the allotment date, you can check your allotment status on the registrar's official website by entering your PAN, application number, or demat account details. Allotment status is also available on the BSE and NSE websites.

The book running lead manager(s) for Sai Parenteral’s IPO are Arihant Capital Markets Ltd.

The promoter(s) of Sai Parenteral’s are Anil Kumar Karusala, Vijitha Gorrepati and Karusala Aruna.

Sai Parenteral’s IPO GMP — What It Means

No grey market premium was recorded for Sai Parenteral’s before it listed.

See the full Sai Parenteral’s GMP history and trend, or learn how grey market premium works and how reliable it is.

Related IPO

Same sector or same stage as Sai Parenteral’s
Side by side: GMP, subscription, valuation, financials and listing performance.
0 Comments

No comments yet. Be the first to share your opinion!

GMPUpdate